The antimicrobial activity of sixteen new N-heteroarylated 1H-(benz)imidazoles was evaluated against clinically relevant bacteria (Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa) and fungi (Candida, Aspergillus and dermatophyte) species according to the Clinical and Laboratory Standards Institute guidelines. None of the tested compounds were active against Gram negative bacteria, but only against S. aureus, that was particularly susceptible to N-thianthrenyl-and N-dibenzothienyl imidazole derivatives. Most of the imidazole derivatives showed a broad spectrum of antifungal activity in all tested fungal strains, including fluconazole-resistant species, with a particularly low minimum inhibitory concentration (MIC) for dermatophytes. (3) showed the highest antifungal potential, being most active against Candida albicans. Some N-heteroarylated benzimidazoles showed low activity for fungi with the exception of 3-(1H-benzo [d]imidazol-1-yl)quinoline (14) which was selective against dermatophytes (MIC=4-16 µg/mL). The effect of the active compounds in the inhibition of the dimorphic transition, ergosterol biosynthesis and mitochondrial activity was evaluated in C. albicans. Compounds 1 and 3 showed the capacity to inhibit the germ tube formation in C. albicans, reduced the ergosterol production and impaired the mitochondrial function. Compounds 1 and 3 showed antimicrobial activity and low cytotoxicity, being of interest for further investigation concerning specially the development of new antifungal agents.
INTRODUCTION
Opportunistic bacterial and fungal infections remain major complications in immunocompromised hosts. Concerning bacteria, Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, as well as species of Enterococcus and Klebsiella are the most commonly involved [1, 2] .
Fungal pathogens are becoming increasingly common [1] . In the last two decades, fungi represent a significant proportion of the etiological agents of serious infections, especially in immunocompromised patients [3] . Although fungal infections contribute substantially to human morbidity and mortality, the impact of these diseases in human health is not widely appreciated [4] . Several species are responsible for systemic infections which kill about one and a half million people every year [4] . Among yeasts and molds, candidiasis, often recurrent, is also an important cause of morbidity and is more severe in immunocompromised patients.
The continued emergence of resistant bacteria is a major public health concern [12] . On the other hand, antifungal drugs often exhibit therapeutic limitations with fungistatic mechanism of action, high toxicity, many drug interactions, insufficient bioavailability and development of resistance or innate resistance by emerging species [13] . Thus, it is imperative to continue the identification and development of new antimicrobial drugs, especially those with new modes of action [12] . In addition, the search for new antifungal drugs, more effective and less toxic than those already in use is required, considering that the currently available agents and the therapeutic outcomes are far from desirable [14, 15] .
N-Arylated imidazoles are found in many biologically active compounds. For instance, some ionizable imidazolylphenyl compounds have been reported to be orally active inhibitors of 5-lipoxygenase [16, 17] . New nitrooxy-substituted 1,5-diarylimidazoles have been endowed with COX-2 inhibitory and vasodilator properties [18] . Some special tetrasubstituted imidazoles have shown to be highly active against important phytopathogens, such as Botrytis cinerea (greymould), Uncinula necator (grape powdery mildew), Mycosphaerella graminicola (wheat leaf blotch) and Alternaria solani (potato and tomato early blight), their fungicidal efficacy due to their ability to promote fungal tubulin polymerization [19] . Numerous imidazole derivatives, such as Schiff bases derived from secnidazole [20] , halogenated imidazoles [21, 22] , and nitroimidazoles [23] , have also already been proved to act as antimicrobials against various pathogens [20] [21] [22] [23] .
Therefore, our research group has recently been interested in the synthesis of several N-heteroarylated(benz)imidazoles, that were described elsewhere [24] .
In this work, we present the screening of sixteen of those N-heteroaryl 1H-(benz)imidazoles, as potential antimicrobial agents against bacteria, dermatophytes, Candida and Aspergillus species with clinical relevance, using the broth microdilution method by Clinical and Laboratory Standards Institute (CLSI). The antifungal activity was evaluated against fluconazole-resistant species such as C. albicans strains, C. krusei, C. glabrata, and Aspergillus species, which are intrinsically resistant to fluconazole or whose resistance is easily inducible. For the compounds showing antifungal activity against C. albicans, we have conducted a study of the effect on dimorphic transition, an important virulence factor in this species. Further investigations to evaluate their effect on ergosterol biosynthesis and mitochondrial activity were also performed. Hemolytic activity was studied to evaluate the cytotoxicity of most active compounds. With the battery of compounds available, it was tried to establish some structure-activity relationships (SARs).
MATERIALS AND METHODS

Compounds
Gentamicine (Sigma) was used as standard antimicrobial drug. Gentamicine was dissolved in 100% dimethyl sulfoxide (DMSO; Sigma) at a starting concentration of 10.24 mg/mL. Amphotericin B (Sigma) and fluconazole (Pfizer) were used as standard antifungal drugs. Amphotericin B was dissolved in 100% DMSO at a starting concentration of 1.6 mg/mL and fluconazole was dissolved in sterile distilled water at 12.8 mg/mL. The tested compounds 1-12 ( Table 1 ) and 13-16 ( Fig. 1) [24] were dissolved in 100% DMSO at 25.6 mg/mL.
The compounds were diluted from stock solution in the test medium to achieve the required test concentrations. The final concentration of DMSO did not exceed 1%. According to previously performed tests (data not shown) DMSO at that concentration did not affect microbial growth.
Microorganisms
The antibacterial activity of compounds 1- 16 , and Epidermophyton floccosum FF9). C. parapsilosis ATCC 90018 was used for quality control. C. albicans ATCC 10231 was used for the germ tube inhibition, inhibition of ergosterol biosynthesis and inhibition of mitochondrial activity assays. The clinical isolates were identified using standard microbiological methods. All bacterial strains were stored in Trypticase soy broth (TSB; Difco) with 15% glycerol at -80 ºC. Fungal strains were stored in Sabouraud dextrose broth (SDB: Liofilchem) with 20% glycerol at -80 ºC. The microorganisms were sub-cultured on Mueller-Hinton Agar 2 (MHA; Biomérieux) for bacteria and Sabouraud dextrose agar (SDA; Biomérieux) for fungi, before use to ensure purity and viability.
Inoculum Preparation
The isolates of bacteria were grown for 24 h, on MHA at 37ºC. The isolates of yeasts, Aspergillus spp. and dermatophytes were grown for 1, 3 and 5 days, respectively, on SDA at 35 ºC for Candida and Aspergillus, and 30 ºC for dermatophytes. Bacteria, yeasts and conidial suspensions from these recent cultures were prepared in sterile 0.85% saline solution. Each suspension was diluted. Bacteria suspensions were diluted using Mueller Hinton broth (MHB; Liofilchem) and fungi in RPMI 1640 medium, with L-glutamine and without sodium bicarbonate (Biochrom AG), buffered to pH 7.0±0.2 with 0.165 M morpholinepropanesulfonic acid (MOPS; Sigma). The inoculum was adjusted to 1-5 × 10 4 colony forming units (CFU)/mL for bacteria, 1-5 x 10 3 CFU/mL for yeasts and 0.4-5 × 10 4 CFU/mL for Aspergillus spp., and 1-3 x 10 3 CFU/mL for dermatophytes, according to CLSI guidelines. 
Antibacterial Susceptibility Testing
Broth microdilution method based on the CLSI (formerly NCCLS) reference document M7-A7, was used to determine minimum inhibitory concentrations (MIC) and minimum lethal concentrations (MLC) [25] . Briefly, the stock solutions of the compounds in DMSO were further diluted in serial twofolds with MHB to a final concentrations ranging from 8 to 512 µg/mL. Equal volumes of cell suspension and compounds dilution were added in the well of a microplate. In addition, gentamicin was used as standard antibacterial drug and controls without compounds, as well as sterility and DMSO control wells, were also included. The plates were incubated aerobically at 37±0.2 ºC for 16-20 h atmospheric humidity.
The MIC values were determined as the lowest concentration of the compound revealed 100% growth inhibition. Besides, quality control was performed by testing the inhibitory activity of gentamicin against E. coli ATCC 25923 (CLSI standard for MIC = 0.25-1 µg/mL).
To measure the MLC, 20 µL of samples were taken from each negative well and the first well exhibiting growth (to serve as a growth control), after MIC reading, spotted onto MHA plates and incubated at 37±0.2ºC for 24 h. The MLC values were determined as the lowest concentration of the compounds causing bacterial death.
All experiments were performed in duplicate and repeated three times, yielding essentially the same results.
Antifungal Susceptibility Testing
Broth microdilution methods based on the CLSI reference documents M27-A3 and M38-A2 for yeasts and filamentous fungi, respectively, with minor modifications, were used to determine MIC and MLC [26, 27] . Briefly, two-fold serial dilutions of each compound were prepared over the range of 8 to 512 μg/mL in RPMI 1640 medium immediately before testing. Equal volumes of cell suspension and compound dilution were added in the well of a microplate and the plates incubated aerobically at 35ºC for 48 h (yeasts and Aspergillus spp.) or at 30 ºC for 5 days (dermatophytes). The fungal growth was indicated by the turbidity and MICs were defined as the lowest drug concentration that reduced growth in 80% in comparison to the compound-free controls. To evaluate the MLCs, 20 µL aliquots were subcultured from each negative well (optically clear) and the last positive well, after MIC reading, onto SDA plates. The plates were then incubated at 35 ºC (yeasts and Aspergillus spp.) or 30 ºC (dermatophytes) until growth was seen in the last positive well subculture. MLC was the lowest concentration of compound yielding subcultures without any visible fungal growth. In addition, a reference antifungal compound, fluconazole or amphotericin B, was used as the standard antifungal drug. Two fold serial dilutions, ranging from 128 to 0.25 μg/mL for fluconazole and 8 to 0.25 μg/mL for amphotericin B, were used. Quality control determinations of the MIC of fluconazole were ensured by testing C. parapsilosis ATCC 90018. The results obtained were within the recommended limits (data not shown). All results are from three independent and concordant experiments, performed in duplicate. A range of values is presented when different results were obtained. Two growth controls, using test medium alone and with 1.0% (v/v) DMSO, and a sterility control (drug-free medium only) were included in all assays.
Germ Tube Inhibition Assay
In order to determine the effect of the most anti-Candida active compounds on dimorphic transition, cell suspensions from overnight SDA culture of C. albicans strain ATCC 10231 were prepared in NYP medium [N-acetylglucosamine (Sigma; 10 -3 mol/L), yeast nitrogen base (Difco; 3.35 g/L), proline (Fluka; 10 -3 mol/L) and NaCl (4.5 g/L), pH 6.7±0.1] [28] and adjusted to obtain a density of (1.0±0.2) × 10 6 CFU/mL. The compounds (1 and 3) were dissolved and diluted in DMSO and added in a volume of 10 μL to 990 µL of the yeast suspensions (final DMSO concentration of 1%) to obtain appropriate sub-inhibitory concentrations (1/2, 1/4 and 1/8 of the MIC). Drug-free control suspensions with 1% DMSO (v/v) were included as control. After incubation at 37 ºC without agitation for 3 h, 100 treated and untreated yeast cells were counted, using a haemocytometer, and the percentage of germinating cells was calculated. A formation of germ tube was considered positive when the germinating tube was at least as long as the diameter of the blastospore. Protuberances showing a constriction at the point of connection to the mother cell, typical for pseudohyphae, were excluded. The results are presented as averages ± standard deviations (SD) of three independent experiments performed in duplicate.
Assessment of Ergosterol Biosynthesis
In order to investigate the effect of compounds 1 and 3 on ergosterol biosynthesis, C. albicans ATCC 10231 were grown in RPMI medium supplemented with 2% glucose (Difco) and incubated at 37 o C in shaking water bath. After incubation with and without compounds at the sub-inhibitory concentrations of (1/2, 1/4, 1/8, 1/16, and 1/32 of the MIC) or 0.25 µg/mL of fluconazole (as a control), yeast cells were collected by centrifugation at 4,000 rpm for 5 min, washed twice with sterile distilled water, dried and weighted. To extract ergosterol, the dry yeast pellet was mixed with 3 mL of a 25% ethanolic KOH solution and incubated at 85 o C for 1 h in a water bath. The saponified sterols were further extracted with hexane. The hexane extract was evaporated under a nitrogen stream and the residue was resuspended in 500 µL of methanol before analysis by HPLC [29] .
Assessment of Mitochondrial Reductase Enzymes
To measure the effect of compounds 1 and 3 on mitochondrial reductase activity of fungi, thiazolyl blue tetrazolium bromide (MTT: [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide]) assay was performed according to the method of Lopes et al. [30] with some modification. Briefly, C. albicans ATCC 10231 cell suspensions were prepared in NaCl 0.85% and the turbidity was adjusted to 0.5 McFarland standard. A 1:50 followed by a 1:20 dilution was performed in RPMI culture medium. 500 µL of RPMI was added to the same volume of the previous cell suspension into a 12 wells plate and incubated overnight (18-24 h at 37 ºC). After the incubation period, cells were carefully homogenate, transferred to eppendorfs and centrifuged at 10,000 rpm for 5 min. The supernatant was removed and 1 mL of the test compound was added to each eppendorf, in the required concentration (2xMIC, MIC, MIC/2, MIC/4, MIC/8, and MIC/16). The mixture was homogenized, transferred to the 12 wells plate and incubated for 1 h at 37 ºC. After the exposure time, cell suspensions were centrifuged, the supernatant removed, and 500 µL of MTT (Sigma-Aldrich, St. Louis, MO, USA) solution (0.5 mg/mL prepared in RPMI) were added to each well and left incubating for 30 min at 37 ºC. The yellow tetrazolium salt MTT is converted by mitochondrial dehydrogenases of metabolically active cells to an insoluble purple formazan product, which was then solubilized with 300 µL of DMSO. The extent of the reduction to formazan within the cells was quantified by measuring the absorbance at 510 nm in a Multiskan Ascent plate reader (Thermo Electron Corporation).
Haemolitic Activity
Human red blood cells from healthy individuals were used to test the hemolytic activity of compounds 1 and 3 according the protocol described by Ahmad et al. [31] . Amphotericin B and fluconazole were used as a commercially antifungal drug.
Statistical Analysis
Data were analyzed by using GraphPad PRISM software (GraphPad software, San Diego, CA, USA) (version 5.02 for Windows). One-way analysis of variance (ANOVA), using the Dunnett Multiple Comparison test, was carried out on data obtained from three independent assays performed in duplicate for each sample. Levels of statistical significance at P<0.05, P<0.01 and P<0.001 were used.
RESULTS AND DISCUSSION
Chemistry
Several N-heteroarylated 1H-(benz)imidazoles 1-12 were obtained through a very efficient, base-free copper (I) oxidecatalyzed N-arylation reaction using B-heteroarylboronic acids in MeOH at room temperature (Fig. 2, Table 1 ) [24] . The method was extended to the use of the most stable 4,4,5,5-tetramethyl-1,3,2-dioxaborolanes as starting materials. Under the same conditions of (Fig. 2) , compounds 13 and 14 from 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline and products 15 and 16 from 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine were prepared (Fig. 1) [24] .
Antibacterial Activity
The MICs and MLCs of the tested and reference (Gentamicine) compounds are presented in Table 2 . Against the Gram negative bacteria, E. coli and P. aeruginosa, no activity was detected for the tested compounds 1-16 at concentrations up to 256 μg/mL. S. aureus (Gram positive) was found to be susceptible to several N-heteroarylimidazoles  1, 3, 5, 11 and to N-heteroarylbenzimidazoles 8 and 12 . These compounds showed a bacteriostatic activity against S. aureus, compounds 3 and 5 being the most active, with a MIC of 8-16 µg/mL. Table 3 for yeasts and Table 4 for filamentous fungi.
Antifungal Activity
Anti-Candida activity ( 1 and 3 (16-256 µg/mL) . Different susceptibility was observed between species, C. albicans being the most susceptible (MIC 16-32 µg/mL), although only fungistatic effect was observed. On the other hand C. tropicalis, C. krusei and C. parapsilosis showed lower susceptibility to the tested compounds. Compounds 1, 8 and 11 were active against all the eight Candida strains tested.
Aspergillus spp. were more resistant than other microorganisms tested, compounds 1, 8, 10, 11 and 12 being active for higher concentrations (MIC 32-256 µg/mL). The sensitivity was similar between the three species of Aspergillus tested. However, dermatophytes, also filamentous fungi, showed the highest susceptibility for compounds 1, 3,  5, 8, 10, 11, 12 , and 14. The lowest MIC values were found for compound 14 against dermatophytes (4-16 µg/mL). Interestingly, this compound showed selectivity for dermatophytes, considering that for bacteria, yeasts and Aspergillus strains the MIC was higher than 256 µg/mL. Compound 5 also showed selectivity for dermatophytes within fungi, although a MIC of 8-16 µg/mL was observed for S. aureus.
Compounds 1, 8, 11 and 12 exhibited the broad spectrum of activity, being active against all the tested strains except Gram negative bacteria. However, compound 1 was, in general, the most active. Compound 10 was active only for fungi and mostly against filamentous fungi. 
Structure-activity Relationships (SARs)
• Analyzing the results it is possible to establish some SARs.
• In general imidazoles are more active than the benzimidazoles.
Imidazoles 3 and 5 bearing a dibenzothien-4-yl and a thiantren-1-yl substituent, respectively, were shown to be the most active compounds against S. aureus, the sulphur atom (one or two) in the central ring and the two fused benzene rings seem to be important for this activity. Despite compounds 3 and 5 being the most active, this bacterium only demonstrated susceptibility to imidazoles with two fused benzene rings and/or benzimidazoles presenting sulphur rings in their structure, compounds 8, 11 and 12. However, in a general way, it may be assumed that Gram positive bacteria are more sensitive to imidazoles.
Against C. albicans the most active imidazoles 1 and 3 have a benzofuran-4-yl and benzothien-4-yl as substituents, respectively, indicating the importance of these substituents in the activity. The presence of a benzimidazole moiety at position 4 of the same substituents (compounds 2 and 4, Table 1 ) completely annuls the antifungal activity of these compounds (Table 3) . Additionally, imidazoles with a dibenzofuran moiety seem to be more effective against Candida species than those with a dibenzothiophene, since they demonstrate activity against a wider range of microorganisms ( Table 3) . For dermatophytes more compounds were active including also benzimidazoles. Benzimidazole 14 bearing a quinoline linked at its 3-position (the corresponding imidazole showing no activity), was selectively active against dermatophytes with low MICs showing no activity neither against bacteria nor against other fungi.
Fluoropyridine derivatives (15) (16) show no activity at all.
As compounds 1 and 3 were shown to be the most promising against Candida species, they were used in assays to further investigate their mechanism of action in C. albicans.
Germ Tube Inhibition
The inhibition of the germ tube formation of yeast is considered to be the mechanism of action of several compounds, as it contributes to the reduction of the microorganism virulence [32] . Compounds 1 and 3 showed a fungistatic activity, with a MLC higher than MIC value, and were objected to further investigations for filamentation inhibitory activity against ATCC type strain of C. albicans (ATCC 10231).
Compounds 1 and 3 prevented germ tube formation, widely regarded as an important mechanism of pathogenicity in this yeast [32] . The highest concentration, MIC (32 µg/mL), caused a complete inhibition in C. albicans ATCC 10231 strain (Fig. 3) and a MIC/2 reduced significantly the germ tube formation. A difference was observed for compounds 1 and 3 in the concentration of 8 µg/mL, with a significant reduction for compound 3 (Fig. 3B ) in comparison to compound 1 (Fig. 3A) . Considering C. albicans, compounds 1 and 3 present the same MIC value (16-32 µg/mL) ( Table 3) , however, the one with a dibenzothiophene moiety (3) is more effective in inhibiting the production of the germ tube by this yeast, presenting a significant reduction, face to untreated control cells, until MIC/4 (P<0.001) (Fig. 3) .
Our results suggest that compound 1 and particularly compound 3 possess not only growth inhibitory effect but also the ability to inhibit morphological transformations in C. albicans. In addition, treatment of C. albicans with sublethal concentrations of these compounds could reduce its pathogenicity by the inhibition of yeast dimorphic transition, which is one of C. albicans virulence mechanisms. As referred above, germ tube is involved in Candida pathogenesis and its inhibition was described to be sufficient to treat disseminated candidiasis [33] . The capacity to inhibit this process, at a concentration lower than MIC, can be useful in the treatment of candidiasis.
Ergosterol Biosynthesis Inhibition
In order to clarify the mechanism of action of the antifungal active compounds, the inhibition of ergosterol biosynthesis was investigated. In this study, the effect of compounds 1 and 3 on ergosterol amount in C. albicans ATCC 10231 was compared to fluconazole drug and 1% DMSO (as a control). After incubation of the yeast with subinhibitory concentrations (16 to 1 μg/mL) of the compounds, differences in the amounts of ergosterol content were observed in treated organism compared to control. However, the reduction of the ergosterol content over 60% found in fluconazole (0.25 μg/mL) treated C. albicans (Fig. 4) was not observed. Some effect seems to occur in ergosterol biosynthesis, with major relevance for compound 3 (Fig. 4B) .
Yeast treated with compound 1 show a tendency to reduce ergosterol amounts with increasing compound concentration. Concerning compound 3, the amount of ergosterol was significantly reduced (P<0.01) when yeasts were exposed to MIC/2 (Fig. 4B) . Once more, the presence of a dibenzothiophene moiety proved to be advantageous face to the dibenzofuran. Even presenting the same MIC value (Table 3) , the ability of compound 3 to reduce the ergosterol in yeast membrane was higher than the one of compound 1, being the ergosterol amount significantly reduced face to untreated control cells (P<0.01) (Fig. 4) .
Ergosterol is a major component of sterol in yeast cell membrane and responsible for maintenance of cell function and integrity [34] . The primary mechanism by which azole antifungal drugs inhibit yeast cell growth is disruption of normal sterol biosynthetic pathways, leading to a reduction in ergosterol biosynthesis [35, 36] . The differences observed in the ergosterol amount of yeast treated with sub-inhibitory concentrations of compounds 1 and 3 (Fig. 4) indicated that a disruption of ergosterol biosynthesis may be involved in the mechanism of action of these compounds although with less importance than by fluconazole.
Mitochondrial Activity Inhibition
In order to determine the effect of compounds 1 and 3 on the metabolic activity of C. albicans ATCC 10231, the evaluation of the extent of reduction of MTT to formazan by the action of mitochondrial reductases was performed [37] . After exposure of the tested yeast cells with various concentrations of compounds 1 and 3, over 50% relative reduction in activity of mitochondrial reductase enzymes was observed for compound 1 at the concentration of 64 µg/mL (2xMIC), when compared to a control (Fig. 5A) . With sub-inhibitory concentrations, the mitochondrial activity was more affected by compound 3 (Fig. 5B) .
Yeast exposure to compounds 1 and 3 lead to a reduction in mitochondrial reductase enzymes activity. For compound 1, the mitochondrial activity was significantly reduced (P<0.001) for 2MIC and MIC. Concerning compound 3, there was also a significant reduction in mitochondrial activity, with P<0.001 for 2MIC-MIC/8 and with P<0.05 for MIC/16. The effect was more evident for compound 3, since it promotes a significant change in yeast metabolic activity at sub-inhibitory concentrations (Fig. 5B) . Once again, the presence of the dibenzothiophene moiety in the molecule seems to be determinant for its activity. This data indicated that the inhibitory mechanism of the compound 3 against C. albicans may be due to, at least in part, by a disruption of mitochondrial enzyme activity which leads to impairment in the energy production ability of yeast cells. The inhibition of mitochondrial dehydrogenases activity affects the respiratory chain of the microorganism and has implications in the production of ATP. Thus, the affectation of the microorganism by enzymatic dysfunction can be, at least, one of the causes of the fungistatic activity of these compounds.
Hemolytic Activity
At 128 μg/mL (MICx4 for C. albicans) compounds 1 and 3 showed 0.7% and 1.1% of hemolysis, respectively. Similar effect was observed for fluconazole at 128 μg/mL, with a % of hemolysis of 0.8. Amphotericin B, at 32 μg/mL, showed 32% of hemolysis. These results indicate that the tested compounds have low cytotoxic activity even for concentrations higher than MIC.
CONCLUSION
Eight of sixteen tested compounds exhibited antimicrobial activity with variable spectrum and potency. Some of them showed a broad spectrum of action extended to all species and strains, while other showed to be selective. The dermatophytes were found to be more sensitive to the active tested compounds than Candida, Aspergillus and bacteria species, with eight of the compounds showing a considerably activity. Among the presented set of compounds, N-(dibenzofuran-4-yl)-1H-imidazole (1) and N-(dibenzothien-4-yl)-1H-imidazole (3) showed the highest potential. Compound 1 inhibited all tested fungal strains, including fluconazole-resistant yeasts and A. fumigatus, which are especially important organisms from the clinical point of view. In fact, its activity was not affected by the fluconazole susceptibility profile of the tested strains. Compounds 1 and 3 were the most active against the three C. albicans strains. The mechanism of action was further confirmed by the prevention of germ tube formation, inhibition of ergosterol biosynthesis and mitochondrial activity in C. albicans ATCC, at sub-inhibitory concentrations. In general, compound 1 exhibited a more gradual effect with increasing concentrations than compound 3.
None of the synthetized compounds seemed promising against the tested Gram negative bacteria. Although, Nheteroarylimidazoles 1, 3, 5, 11, and N-heteroarylbenzimidazoles 8 and 12 showed activity against S. aureus. Particularly, imidazoles 3 and 5 were found to be good candidates for further studies, considering infections and coinfections with this microorganism.
With the battery of sixteen N-heteroarylated 1H-(benz) imidazoles compounds tested it was possible to establish some structure-activity relationships. Given the results described, and as a future perspective, the structure-activity oriented preparation of a wider set of derivatives could, probably, allow the tuning of the antifungal activity of the compounds, particularly regarding the reduction of MICs for yeasts and Aspergillus species. Overall, these compounds, particularly imidazoles 1 and 3, showed an interesting potential for development as antifungal agents and certainly deserve further investigation.
